1. Bexobrutideg shows 75% response rate in Waldenström macroglobulinemia patients. 2. Durable responses observed, with ongoing treatment exceeding six months for some. 3. Well-tolerated with low-grade adverse events; no new major toxicity reported. 4. Bexobrutideg could become a best-in-class therapy for certain hematologic malignancies. 5. Nurix is advancing multiple similar drug programs enhancing pipeline diversification.
FAQ
Why Bullish?
The promising clinical results for bexobrutideg can positively influence NRIX’s market position, reminiscent of historical surges seen after positive clinical trial data disclosures. For instance, similar biotech firms have seen stock upticks after announcing favorable Phase trial results.
How important is it?
The article highlights significant advancements in clinical trials which could directly influence NRIX's valuation and investor sentiment, making it a crucial update for stakeholders.
Why Long Term?
The ongoing development and updates regarding bexobrutideg will potentially lead to sustained interest in the stock, as long-term efficacy and tolerability data emerge, similar to how other biotech stocks have climbed post successful multi-phase trials.
Nurix Therapeutics Announces Promising Phase 1 Results for Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia
On December 8, 2025, Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, presented significant new clinical findings from its Phase 1 trial involving bexobrutideg (NX-5948), aimed at treating relapsed or refractory Waldenström macroglobulinemia (WM). This pivotal data was shared during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, highlighting the efficacy and safety of this innovative therapeutic approach.
Key Trial Outcomes
The clinical trial showcased an impressive objective response rate (ORR) of 75.0% among patients, which included three very good partial responses (VGPR). Notably, with a median follow-up period of 8.1 months, the study has yet to reach a median duration of response (DOR) or median progression-free survival (PFS), indicating ongoing treatment benefits.
- Patient Demographics: The trial involved 31 patients, with a median age of 71 years.
- Prior Treatments: All patients had previously received a Bruton’s tyrosine kinase (BTK) inhibitor, and most underwent chemotherapy or other treatments.
- Adverse Events (AEs): Predominantly low-grade events were reported, with the most common including neutropenia (29.0%) and anemia (22.6%).
Expert Commentary on the Findings
Dr. Paula G. O’Connor, Chief Medical Officer of Nurix, emphasized the encouraging activity of bexobrutideg in this heavily pre-treated population, stating, “The data presented at ASH demonstrate durable and deepening responses with longer time on treatment.”
Furthermore, Arthur T. Sands, M.D., Ph.D., President and CEO of Nurix, commented, “These clinical data and our insights into bexobrutideg’s unique properties bolster our belief that it could be a best-in-class therapeutic option for patients with WM and other hematologic malignancies.”
Future Developments and Webcast Information
Nurix plans to continue development on bexobrutideg as a promising new treatment option for WM, chronic lymphocytic leukemia (CLL), and potentially other indications. A live webcast to discuss these developments and provide further corporate updates is scheduled for 8:15 p.m. ET on December 8, 2025. Attendees can access the event via the Investor section of Nurix’s website.
About Bexobrutideg (NX-5948) and Nurix Therapeutics
Bexobrutideg is an investigational oral medication designed as a highly selective BTK degrader. It is currently under evaluation in both the DAYBreak CLL-201 Phase 2 trial for CLL and the NX-5948-301 Phase 1a/1b trial for B cell malignancies.
Nurix Therapeutics specializes in developing targeted protein degradation therapies with the aim of improving treatment options for patients suffering from cancer and inflammatory diseases. Their innovative pipeline includes multiple drug candidates that leverage cutting-edge biopharmaceutical technologies.